ARROWHEAD PHARMACEUTICALS, INC. (ARWR) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 1 fund adding, and 2 funds trimming or exiting versus the previous quarter. Latest close $43.11 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
Avoro Capital Advisors · Deerfield Management · Baker Bros. Advisors — 5 tracked funds hold ARWR. See all holders.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
Celcuity Inc. (CELC) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX) · XENON PHARMACEUTICALS INC (XENE) · Dianthus Therapeutics, Inc. /DE/ (DNTH) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Avoro Capital Advisors | 8.31% | 11,355,555 | ADDED (+6.1%) Q3 filed Nov 16 |
| Deerfield Management | 1.18% | 1,389,055 | TRIMMED (-11.7%) Q3 filed Nov 16 |
| Baker Bros. Advisors | 0.81% | 1,992,783 | HELD Q3 filed Nov 16 |
| Edgewood Management | 0.02% | 25,000 | HELD Q3 filed Nov 12 |
| Polen Capital Management | <0.01% | 6,612 | NEW Q3 filed Nov 13 |
| RTW Investments | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -46.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 505 of 8,857 filers |
| Long-only filers among them | 498 |
| Change vs 2026 Q1 | +74 net · 480 entered · 406 exited |
| Shares reported, all filers | 119,163,036 |
| Reported value, all filers | $9.7B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $829.4M |
| Net income · FY2025 | $-1.6M |
| Total assets · FY2025 | $1.4B |
| Shares outstanding | 141,254,467 |
| Market cap (at latest close) | $6.1B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.
| Shares short · Oct 15, 2026 | 10,959,276 |
| Share of shares outstanding | 7.76% |
| Days to cover | 5.36 |
Shares short at recent settlements — Jul 31, 2026: 9.7M · Aug 14, 2026: 9.2M · Aug 31, 2026: 9.4M · Sep 15, 2026: 9.3M · Sep 30, 2026: 10.8M · Oct 15, 2026: 11.0M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 671 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Aug 18, 2026 | Adeoye Olukotun | Director | 2,000 | $173.9K | Aug 18, 2026 | SEC filing |
| Aug 18, 2026 | Michael Perry | Director | 11,600 | $1.0M | Aug 18, 2026 | SEC filing |
| May 19, 2026 | Daniel Apel | Officer | 13,095 | $934.2K | Apr 22, 2026 | SEC filing |
| May 19, 2026 | Hongbo Lu | Officer | 2,970 | $228.3K | May 12, 2026 | SEC filing |
| May 19, 2026 | James Hamilton | Officer | 10,000 | $750.0K | Apr 23, 2026 | SEC filing |
| May 12, 2026 | Hongbo Lu | Officer | 2,970 | $228.3K | May 12, 2026 | SEC filing |
| Apr 23, 2026 | James Hamilton | Officer | 10,000 | $750.0K | Apr 23, 2026 | SEC filing |
| Apr 22, 2026 | Daniel Apel | Officer | 13,095 | $934.2K | Apr 22, 2026 | SEC filing |
| Mar 5, 2026 | James Hamilton | Officer | 10,000 | $641.9K | Mar 5, 2026 | SEC filing |
| Jan 5, 2026 | James Hamilton | Officer | 40,164 | $2.5M | Jan 5, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Aug 15, 2025 | SCHEDULE 13D/A | +115.9% (close Aug 18, 2025 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Aug 18, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Avoro Capital Advisors LLC | SC 13G/A | 13,823,383 | 9.6% | Jun 30, 2026 | SEC filing |
| Jul 31, 2026 | Vanguard Portfolio Management | SC 13G/A | 6,384,903 | 4.5% | Jun 30, 2026 | SEC filing |
| Jul 27, 2026 | BlackRock, Inc. | SC 13G/A | 14,232,545 | 10.1% | Jun 30, 2026 | SEC filing |
| May 6, 2026 | FMR LLC | SC 13G | 7,349,106.75 | 5.2% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 7,081,293 | 5.0% | Mar 31, 2026 | SEC filing |
| Apr 28, 2026 | Vanguard Portfolio Management | SC 13G | 7,269,957 | 5.2% | Mar 31, 2026 | SEC filing |
| Apr 24, 2026 | BlackRock, Inc. | SC 13G/A | 17,104,084 | 12.2% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Jan 21, 2026 | BlackRock, Inc. | SC 13G/A | 20,323,221 | 15.0% | Dec 31, 2025 | SEC filing |
| Aug 15, 2025 | Sarepta Therapeutics, Inc. | SC 13D/A | 0 | 0.0% | Aug 13, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
This stock does not currently pass any tracked screen.
Also held by the tracked funds that hold ARWR — ranked by lift, the co-holding pattern described in Methodology: Celcuity Inc. (CELC) · Mirum Pharmaceuticals, Inc. (MIRM) · Praxis Precision Medicines, Inc. (PRAX) · XENON PHARMACEUTICALS INC (XENE) · Dianthus Therapeutics, Inc. /DE/ (DNTH) · STRUCTURE THERAPEUTICS INC (GPCR) · Taysha Gene Therapies, Inc. (TSHA) · REVOLUTION MEDICINES INC (RVMD).
Filings audit: every filing lens on ARROWHEAD PHARMACEUTICALS, INC. (ARWR), scored — GetCoattail Research.
| Filed | Items | Source |
|---|---|---|
| Nov 12, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Nov 4, 2026 | 1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation | SEC filing |
| Aug 4, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Celcuity Inc. (CELC) · Filings audit: every filing lens on ARROWHEAD PHARMACEUTICALS, INC. (ARWR), scored · Practice timing on ARWR
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.